This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Milas, L. Articles by Peters, L. J. Search for Related Content PubMed PubMed Citation Articles by Milas, L. Articles by Peters, L. J.

Role of Reoxygenation in Induction of Enhancement of Tumor Radioresponse by Paclitaxel¹

Departments of Experimental [L. M., N. R. H., K. A. M., C. G. M., Y. S.] and Clinical Radiotherapy [L. J. P.], The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030

We reported previously (L. Milas et al., Cancer Res., 54: 3506–3510, 1994) that paclitaxel greatly enhances the response of a murine mammary carcinoma to subsequent irradiation and hypothesized that the enhanced radioresponse was mediated by tumor cell reoxygenation caused by treatment with paclitaxel. Because paclitaxel induced massive tumor cell destruction by apoptosis, it was reasoned that as apoptotic cells were removed from the tumor more hypoxic cells would have access to oxygen, be reoxygenated, and, thus, become more sensitive to radiation. The present study tested this hypothesis by assessing the effect of 60 or 40 mg/kg paclitaxed on radioresponse of an 8-mm MCA-4 tumor irradiated under air-breathing or hypoxic conditions 9, 24, 48, or 72 h after paclitaxel administration. If the hypothesis was correct, paclitaxel would enhance tumor radioresponse more under air breathing than under hypoxic conditions, and the enhancement would increase as the time between paclitaxel administration and tumor irradiation increased within a few days after paclitaxel treatment but only when radiation was given under air-breathing conditions.

The effect of the treatments was determined by tumor growth delay and the radiation dose required to control 50% of the tumors (TCD₅₀). Paclitaxel greatly enhanced tumor radioresponse under air-breathing (and not hypoxic) conditions, increasing tumor growth delay, and reducing TCD₅₀. These effects increased as the time interval between paclitaxel administration and tumor irradiation increased within the observation period of 72 h after paclitaxel treatment. The enhancement factors for tumor growth delay ranged from 1.19 at 9 h to 1.86 at 48 h and for TCD₅₀, from 1.16 at 9 h to 1.47 at 72 h after paclitaxel. Direct measurements of tumor pO₂ showed a median value in untreated tumors of 6.2 mmHg, which increased to 10.5 mmHg at 24 h and to 31.2 mmHg at 48 h after paclitaxel administration. Overall, these results show that paclitaxel is a potent enhancer of tumor radioresponse and that its effect is mediated by reoxygenation of hypoxic tumor cells.

¹ This investigation was supported by NIH Research Grants CA-06294 and CA-16672.

² To whom requests for reprints should be addressed, at M. D. Anderson Cancer Center, Department of Experimental Radiotherapy, Box 66, 1515 Holcombe Boulevard, Houston, TX 77030.

Received 3/21/95. Accepted 6/19/95.

This article has been cited by other articles:

				A. M. Gonzalez-Angulo and G. N. Hortobagyi Optimal Schedule of Paclitaxel: Weekly Is Better J. Clin. Oncol., April 1, 2008; 26(10): 1585 - 1587. [Full Text] [PDF]

				A. Wouters, B. Pauwels, F. Lardon, and J. B. Vermorken Review: Implications of In Vitro Research on the Effect of Radiotherapy and Chemotherapy Under Hypoxic Conditions Oncologist, June 1, 2007; 12(6): 690 - 712. [Abstract] [Full Text] [PDF]

				N. Wiedenmann, D. Valdecanas, N. Hunter, S. Hyde, T. A. Buchholz, L. Milas, and K. A. Mason 130-nm Albumin-Bound Paclitaxel Enhances Tumor Radiocurability and Therapeutic Gain Clin. Cancer Res., March 15, 2007; 13(6): 1868 - 1874. [Abstract] [Full Text] [PDF]

				Z. Liao, R. Komaki, L. Milas, C. Yuan, M. Kies, J. Y. Chang, M. Jeter, T. Guerrero, G. Blumenschien, C. M. Smith, et al. A Phase I Clinical Trial of Thoracic Radiotherapy and Concurrent Celecoxib for Patients with Unfavorable Performance Status Inoperable/Unresectable Non-Small Cell Lung Cancer Clin. Cancer Res., May 1, 2005; 11(9): 3342 - 3348. [Abstract] [Full Text] [PDF]

				A. G. Taghian, R. Abi-Raad, S. I. Assaad, A. Casty, M. Ancukiewicz, E. Yeh, P. Molokhia, K. Attia, T. Sullivan, I. Kuter, et al. Paclitaxel Decreases the Interstitial Fluid Pressure and Improves Oxygenation in Breast Cancers in Patients Treated With Neoadjuvant Chemotherapy: Clinical Implications J. Clin. Oncol., March 20, 2005; 23(9): 1951 - 1961. [Abstract] [Full Text] [PDF]

				E. L. Jones, L. R. Prosnitz, M. W. Dewhirst, P. K. Marcom, P. H. Hardenbergh, L. B. Marks, D. M. Brizel, and Z. Vujaskovic Thermochemoradiotherapy Improves Oxygenation in Locally Advanced Breast Cancer Clin. Cancer Res., July 1, 2004; 10(13): 4287 - 4293. [Abstract] [Full Text] [PDF]

				P. Sonveaux, C. Dessy, P. Martinive, X. Havaux, B. F. Jordan, B. Gallez, V. Gregoire, J.-L. Balligand, and O. Feron Endothelin-1 Is a Critical Mediator of Myogenic Tone in Tumor Arterioles: Implications for Cancer Treatment Cancer Res., May 1, 2004; 64(9): 3209 - 3214. [Abstract] [Full Text] [PDF]

				W. Sun, J. P. Stevenson, M. L. Gallagher, D. Vaughn, S. M. Hahn, D. G. Haller, M. Cohen, J. Kopit, G. Gallant, and P. J. O'Dwyer Phase I and Pharmacokinetic Trial of the Novel Taxane BMS-184476 Administered as a 1-Hour Intravenous Infusion in Combination with Cisplatin Every 21 Days Clin. Cancer Res., November 1, 2003; 9(14): 5221 - 5227. [Abstract] [Full Text] [PDF]

				F. Kraeber-Bodere, C. Sai-Maurel, L. Campion, A. Faivre-Chauvet, E. Mirallie, M. Cherel, S. Supiot, J. Barbet, J.-F. Chatal, and P. Thedrez Enhanced Antitumor Activity of Combined Pretargeted Radioimmunotherapy and Paclitaxel in Medullary Thyroid Cancer Xenograft Mol. Cancer Ther., February 1, 2002; 1(4): 267 - 274. [Abstract] [Full Text] [PDF]

				A. G. Taghian, S. I. Assaad, A. Niemierko, I. Kuter, J. Younger, R. Schoenthaler, M. Roche, and S. N. Powell Risk of Pneumonitis in Breast Cancer Patients Treated With Radiation Therapy and Combination Chemotherapy With Paclitaxel J Natl Cancer Inst, December 5, 2001; 93(23): 1806 - 1811. [Abstract] [Full Text] [PDF]

				D. I. Rosenthal, J. H. Lee, R. Sinard, D. A. Yardley, M. Machtay, D. M. Rosen, M. J. Egorin, R. S. Weber, G. S. Weinstein, A. A. Chalian, et al. Phase I Study of Paclitaxel Given by Seven-Week Continuous Infusion Concurrent With Radiation Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck J. Clin. Oncol., March 1, 2001; 19(5): 1363 - 1373. [Abstract] [Full Text] [PDF]

				J. B. Sunwoo, L. L. Herscher, G. S. Kroog, G. R. Thomas, F. G. Ondrey, D. C. Duffey, B. I. Solomon, C. Boss, P. S. Albert, L. McCullugh, et al. Concurrent Paclitaxel and Radiation in the Treatment of Locally Advanced Head and Neck Cancer J. Clin. Oncol., February 1, 2001; 19(3): 800 - 811. [Abstract] [Full Text] [PDF]

				K. A. Mason, K. Kishi, N. Hunter, L. Buchmiller, T. Akimoto, R. Komaki, and L. Milas Effect of Docetaxel on the Therapeutic Ratio of Fractionated Radiotherapy in Vivo Clin. Cancer Res., December 1, 1999; 5(12): 4191 - 4198. [Abstract] [Full Text] [PDF]

				T. Akimoto, N. R. Hunter, L. Buchmiller, K. Mason, K. K. Ang, and L. Milas Inverse Relationship between Epidermal Growth Factor Receptor Expression and Radiocurability of Murine Carcinomas Clin. Cancer Res., October 1, 1999; 5(10): 2884 - 2890. [Abstract] [Full Text] [PDF]

				B. Kurdoglu, N. Cheong, J. Guan, B. W. Corn, W. J. Curran Jr., and G. Iliakis Apoptosis as a Predictor of Paclitaxel-induced Radiosensitization in Human Tumor Cell Lines Clin. Cancer Res., September 1, 1999; 5(9): 2580 - 2587. [Abstract] [Full Text] [PDF]

				G. Griffon-Etienne, Y. Boucher, C. Brekken, H. D. Suit, and R. K. Jain Taxane-induced Apoptosis Decompresses Blood Vessels and Lowers Interstitial Fluid Pressure in Solid Tumors: Clinical Implications Cancer Res., August 1, 1999; 59(15): 3776 - 3782. [Abstract] [Full Text] [PDF]

				A. Niero, E. Emiliani, G. Monti, F. Pironi, L. Turci, A. M. Valenti, and M. Marangolo Paclitaxel and Radiotherapy: Sequence-dependent Efficacy--A Preclinical Model Clin. Cancer Res., August 1, 1999; 5(8): 2213 - 2222. [Abstract] [Full Text] [PDF]

				L. Milas, T. Fujii, N. Hunter, M. Elshaikh, K. Mason, W. Plunkett, K. K. Ang, and W. Hittelman Enhancement of Tumor Radioresponse in Vivo by Gemcitabine Cancer Res., January 1, 1999; 59(1): 107 - 114. [Abstract] [Full Text] [PDF]